PT  - JOURNAL ARTICLE
AU  - KIYOSHI MAEDA
AU  - MASATSUNE SHIBUTANI
AU  - HIROSHI OTANI
AU  - TATSUNARI FUKUOKA
AU  - YASUHITO ISEKI
AU  - SHINJI MATSUTANI
AU  - HISASHI NAGAHARA
AU  - TORU INOUE
AU  - AKIKO TACHIMORI
AU  - TAKAFUMI NISHII
AU  - YOSHITAKA MIKI
AU  - MASAKO HOSONO
AU  - MASAICHI OHIRA
TI  - Neoadjuvant Radiotherapy with Capecitabine Plus Bevacizumab for Locally Advanced Lower Rectal Cancer: Results of a Single-institute Phase II Study
AID  - 10.21873/anticanres.12713
DP  - 2018 Jul 01
TA  - Anticancer Research
PG  - 4193--4197
VI  - 38
IP  - 7
4099  - http://ar.iiarjournals.org/content/38/7/4193.short
4100  - http://ar.iiarjournals.org/content/38/7/4193.full
SO  - Anticancer Res2018 Jul 01; 38
AB  - Background/Aim: A single-arm phase II clinical trial was conducted to evaluate the safety and efficacy of adding bevacizumab to standard capecitabine-based neoadjuvant chemoradiotherapy (CRT) for the treatment of locally advanced rectal cancer (LARC). Patients and Methods: Twenty-five patients were enrolled. Patients received capecitabine-based CRT for 5 weeks and 3 days. Bevacizumab was administered every 2 weeks during CRT. Within 6-10 weeks after completion of CRT, surgery was performed. Results: With regard to CRT-related acute toxicities, most of the adverse events were limited to grade 1. A pathological complete response was obtained in four (16%) patients. In total, six patients (24%) developed postoperative complications. Six out of five (83%) patients healed without the need for surgical intervention. Conclusion: Although acute toxicity during CRT with bevacizumab was minimal and postoperative complications do not seem to increase, the addition of bevacizumab apparently offers no clinically-significant benefit for patients with LARC.